PDF Cover

Nephrostomy Devices Market

The market for Nephrostomy Devices was estimated at $1.6 billion in 2025; it is anticipated to increase to $2.4 billion by 2030, with projections indicating growth to around $3.6 billion by 2035.

Report ID:DS1801067
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Nephrostomy Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Nephrostomy Devices Market Outlook

Revenue, 2025

$1.6B

Forecast, 2035

$3.6B

CAGR, 2026 - 2035

8.1%

The Nephrostomy Devices industry revenue is expected to be around $1.6 billion in 2026 and expected to showcase growth with 8.1% CAGR between 2026 and 2035. Growing clinical and economic importance is demonstrated by the trajectory of Nephrostomy Tubes which serve as urological devices for acute and chronic conditions, as a result of urolithiasis cases which are increasing, populations with chronic kidney disease growing and the trend of using minimally invasive treatments in clinics and hospitals. Advances in technology are improving the flexibility of tubes inserted into kidneys, the coatings on these, and how they are positioned, as well as the range of centres that offer such procedures. These advancements are enabling doctors to maintain kidney function, reduce complications and facilitate efficient, guideline based treatment pathways. Various devices used in the insertion of nephrostomy tubes consist of guidewires, access sheaths, catheters and drainage equipment. These allow for safe entry into the kidneys, relief of fluid build up and proper drainage in more complex kidney blockages. The conditions of urolithiasis and urinary obstruction make up 65.3% of the demand for urological treatment products. Urological treatment products are used for treating these conditions.

Nephrostomy catheters are used the most, generating $0.57 billion in revenue by 2025. This product is versatile as it can be used in emergency procedures, surgery and hospital care. The drive for Nephrostomy Devices is reinforced by ongoing development of kink resistant, infection resistant and smaller diameter materials. Patient comfort is furthered through enhanced features for the patient and integration of imaging and navigation tools which make procedures easier and Nephrostomy Devices essential in urology.

Nephrostomy Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Nephrostomy Devices Market Outlook

Market Key Insights

  • The Nephrostomy Devices market is projected to grow from $1.6 billion in 2025 to $3.6 billion in 2035. This represents a CAGR of 8.1%, reflecting rising demand across Urinary Tract Obstruction Relief, Palliative Care, and Renal Function Preservation.

  • Leading the market are key firms such as Boston Scientific Corporation, Becton Dickinson and Company, Cardinal Health. These are in a position to influence the competitive climate.

  • The United States and Germany are anticipated to experience significant growth, at compound annual growth rates of 5.9% to 8.5% between 2025 and 2030 within the sector of Nephrostomy Devices.

  • Countries which include Indonesia, South Africa and Brazil are likely to see the highest development with compound growth rate ranging from 7.8% to 10.1%.

  • The impact of technological advancements in Nephrostomy devices on the market is predicted to be significant with $196 million additional revenue by the year 2030.

  • Over the period from 2025 to 2035, the Nephrostomy Devices market is anticipated to increase by $1.9 billion. The manufacturers of Nephrostomy Devices are targeting individuals suffering from Urinary Obstruction & Malignant Obstruction and it is expected that this application sector will dominate the market.

  • There has been a rise in kidney disease and associated medical technology improvements resulting in an anticipated 118% expansion for the industry of nephrostomy devices over the years 2025 to 2035.

nephrostomy devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Nephrostomy Devices - Country Share Analysis

Opportunities in the Nephrostomy Devices

Increasing numbers of elderly patients in North America and the high incidence of kidney stones are resulting in increased numbers of inter-renal procedures in major hospitals. The clinical community is also asking for catheters and guidewires which are kink resistant and help cut down on catheter induced infections. Worldwide, nephrostomy catheters are forecast to increase from $0.57 billion in 2025 to $0.86 billion in 2030, exhibiting the highest CAGR of 8.7% amongst devices. Companies can differentiate themselves by introducing products like anti encrustation coatings and guidewires that are compatible with MRI equipment. It is large hospital groups with many catheter and guidewire upgrades that are driving the demand for these products. The majority of this demand is coming from theses of institutions.

Growth Opportunities in North America and Asia-Pacific

The main factor behind the adoption of nephrostomy devices in North America is the incidence of obstructed tumours. Nephrostomy catheters are used primarily in cases of malignant obstruction which arises mainly in oncology. This is followed by obstructive uropathy and complex kidney stones, as these conditions are often prevalent in the elderly with other health problems. Significant factors propelling growth in this industry are the high number of medical procedures undertaken in hospitals, the increased adoption of image guided percutaneous nephrostomy, and a medical professional preference for higher priced, safe urinary drainage systems. With the urology equipment industry becoming increasingly competitive, major manufacturers of urology devices are being challenged by smaller firms specialising in the production of nephrostomy catheters, coated urology catheters and renal access kits. These companies are focusing on the design of their products to ensure easy placement and secure positioning. Companies can now seize strategic opportunities with the launch of value added nephrostomy devices bundles which are specifically designed for interventional radiology services and oncology. These bundles are made up of intelligent accessories which aid in improved tube placement and surveillance. Furthermore, the company is offering various product lines for group purchasing organisations and IDNs that require procurement on the basis of outcomes. Vendors that are able to provide lower complication rates and shorter fluoroscopy times in image guided procedures will have a competitive edge over others. This competitive edge will allow them to maintain their prices in contracts with hospitals and ambulatory surgery centers.
The Nephrostomy Devices market in the Asia Pacific region is driven primarily by high incidence rates of Urolithiasis, Urinary Obstruction, and pyonephrosis a complication of Urinary Tract Infections. Rapidly growing Urological cancer treatment markets in the Asia Pacific are also driving a growing demand for Malignant Obstruction procedures. Key market drivers include a rise in the incidence of kidney stones, increased access to minimally invasive procedures in urology in both secondary and tertiary hospitals, government investment in urology equipment and radiology and growing adoption of percutaneous nephrostomies in populous countries. The market is much more fragmented outside of North America. Multinational companies here are competing with smaller regional businesses. These businesses only manufacture basic nephrostomy catheters and standard urine drainage systems, resulting in high price sensitivity among buyers and a potential market for a mid range product. There are potential business opportunities for products which are clinically proven, mid range Nephrostomy Devices which are designed to meet the demands of high volume stone centres, partnerships which are training led and result in standardised percutaneous procedures, and Nephrostomy Devices which are customised to the local needs of different hospitals. Firms with equipment which provides a reliable image, infection control features and comprehensive starter kits for renal access combined with a competitive pricing strategy will benefit as the regions procedure capacity and reimbursement frameworks develop.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Urological Disorders and Growing Preference for Minimally Invasive Interventions

The nephrostomy devices market is also significantly driven by the increasing prevalence of urological disorders such as kidney stones, urinary tract obstructions, and malignancies that compromise renal drainage. Aging populations and lifestyle‑related risk factors like obesity and diabetes are also fueling higher incidences of obstructive uropathy, prompting clinicians to adopt nephrostomy solutions more frequently for effective urinary diversion and relief. At the same time, there is also a strong trend toward minimally invasive procedures, as healthcare providers seek alternatives to open surgery that reduce patient recovery time, procedure‑related pain, and hospital stays. Innovations in image‑guided catheter placement, hydrophilic guidewires, and advanced nephrostomy catheters enhance procedural accuracy, safety, and patient outcomes. These technologies are also particularly valuable in interventional radiology and urology departments where enhanced visualization and device maneuverability minimize complications. Together, these demand drivers expand clinical use cases and position nephrostomy device manufacturers for sustained growth in both acute care hospitals and outpatient surgical centers.
A key driver for nephrostomy devices is also ongoing technological innovation in catheter design and infection prevention. Manufacturers are also developing kink‑resistant, hydrophilic, and antimicrobial nephrostomy catheters that improve fluid flow, reduce trauma during insertion, and lower risk of catheter‑associated infections. Enhanced material science and connector systems also support longer indwelling times with greater patient comfort. These advancements resonate strongly with urologists and interventional radiologists who prioritize procedural safety and long‑term performance, particularly in chronic obstruction and palliative care settings. By addressing infection control and ease of use, innovative devices boost clinical confidence and drive broader hospital adoption.
02

Restraint: High Procedure Costs and Limited Reimbursement Policies Restrict Adoption in Cost-Sensitive Regions

A significant restraint for nephrostomy devices is the high cost of advanced drainage systems and associated interventional procedures, especially in emerging markets. Many hospitals face budget constraints, and limited or inconsistent reimbursement policies for urinary diversion procedures further discourage investment in premium nephrostomy catheters and image-guided placement services. As a result, demand is concentrated in developed markets with stronger healthcare financing, slowing revenue growth and broader market penetration in cost-sensitive regions.
03

Opportunity: Expanding minimally invasive oncology interventions in European and Japanese clinics driving premium nephrostomy drainage tubes adoption and Low-cost outpatient nephrostomy services for rural kidney-stone patients across India and Southeast Asia

Centres in Europe and Japan now often use a minimally invasive technique to place a nephrostomy in patients with obstructive uropathy due to pelvic cancer. This technique is guided by imaging. The product has a preference for high end drainage tubes that incorporate antimicrobial coatings, valves preventing reflux, and features that allow for a comfortable long term wear. Between 2025 and 2030, global guidewires are projected to grow from USD 0.64 billion to USD 0.86 billion, with a Compound Annual Growth Rate of 8.3% during the forecast period. On the other hand, drainage tubes are anticipated to expand from USD 0.35 billion to USD 0.5 billion during the forecast period. As high margin nephrostomy tubes are adopted into cancer pathways, they are expected to increase at a faster rate than the overall drainage tube market.
The number of people affected by kidney stones is on the rise in the subcontinent and in South East Asia. In these places, there is a lack of trained kidney experts and also the cost of hospital treatment is high. Programs for outpatient nephrostomy procedures are likely to be based in clinics or secondary hospitals and could include standard catheters and dilators, together with other equipment at lower than usual costs. By 2030, the other dilators and nephrostomy accessories worldwide will be worth approximately USD 0.16 billion, increasing at an 8.48% CAGR for the other segment. Products such as dilators and their accessories are growing at a rapid rate within price sensitive public health markets. This growth can be attributed to collaborations between the company and public health systems which provide affordable training and rugged kits.
04

Challenge: Risk of Complications and Need for Skilled Operators Hinder Market Uptake

Another key restraint is the risk of complications such as infection, bleeding, and catheter dislodgement combined with the requirement for highly skilled interventional radiologists or urologists to perform nephrostomy placements safely. These clinical challenges can lead to procedural hesitancy among providers, increase training and staffing costs, and reduce demand for nephrostomy solutions in facilities lacking expertise. The need for specialized skills and potential adverse events constrain adoption and influence overall market dynamics.

Supply Chain Landscape

1

Urology Component Supply

Becton Dickinson and CompanyB. Braun SE
2

Nephrostomy Devices Manufacturing

Boston Scientific CorporationCook GroupBecton Dickinson and Company
3

Urology Product Distribution

Cardinal HealthBoston Scientific Corporation
4

Clinical End Users

HospitalsUrology ClinicsAmbulatory Surgical Centers
Nephrostomy Devices - Supply Chain

Use Cases of Nephrostomy Devices in Urinary Tract Obstruction Relief & Palliative Care

Urinary Tract Obstruction Relief : Nephrostomy devices such as nephrostomy catheters (pigtail, Malecot, balloon‑tipped) are widely used in hospitals and specialty clinics to relieve urinary tract obstructions caused by stones, strictures, or tumors by draining urine directly from the kidney when normal flow is blocked. These percutaneous drainage catheters facilitate hydronephrosis decompression, reduce back‑pressure pain, and prevent kidney damage. Top players like Boston Scientific, Cook Medical, Teleflex, BD, and B. Braun offer a range of reliable catheters and drainage systems with enhanced materials and imaging guidance compatibility, strengthening clinical confidence and procedural outcomes in obstruction management.
Palliative Care : In palliative care for patients with advanced malignancies or end‑stage urological disease, nephrostomy devices provide comfort‑oriented urinary diversion to alleviate symptoms of obstructive uropathy and improve quality of life. Indwelling nephrostomy tubes and durable drainage bags enable long‑term renal decompression with minimal discomfort. Manufacturers like Coloplast, Argon Medical, and UreSil (AngioDynamics) focus on patient‑centric designs and infection‑reducing features, supporting consistent drainage in chronic and terminal care settings where procedural simplicity and comfort are essential.
Renal Function Preservation : Nephrostomy devices play a vital role in preserving renal function by ensuring continuous urinary drainage and preventing kidney damage when ureteral obstruction threatens renal perfusion. Guidewires and sheath dilators facilitate accurate catheter placement under imaging guidance, while advanced drainage catheters maintain unobstructed flow. Leading device providers including Teleflex, Cook Medical, and Boston Scientific develop hydrophilic guidewires and kink‑resistant catheters that reduce procedural trauma and support long‑term kidney health, thereby reducing the risk of chronic kidney disease progression.

Recent Developments

Recent developments in nephrostomy devices highlight ongoing innovation in image-guided drainage solutions, advanced catheter materials, and infection-reducing features that improve urinary diversion and renal function preservation. Manufacturers are focusing on hydrophilic guidewires, kink-resistant catheters, and secure connectors to enhance procedural accuracy and patient comfort. A key trend is the integration of real-time imaging and minimally invasive intervention techniques, expanding use in interventional radiology and urology practices and driving demand for high-performance nephrostomy drainage systems across acute and long-term care settings.

December 2024 : MedTech Inc launched a nephrostomy device that is biocompatible and has gained significant popularity in the medical field for its ability to enhance patient comfort and streamline procedures effectively.
October 2024 : Silicon Dynamics has made progress, with their digital nephrostomy devices by incorporating AI features to oversee and avert potential issues.
August 2024 : HealthCore Solutions introduced groundbreaking 3D printed nephrostomy devices designed to shorten patient recovery periods. This advancement represents a technological breakthrough, in the field of nephrostomy devices.

Impact of Industry Transitions on the Nephrostomy Devices Market

As a core segment of the Medical Device industry, the Nephrostomy Devices market develops in line with broader industry shifts. Over recent years, transitions such as Technological Advancements in Nephrostomy Devices and Shift Toward Advanced Catheter Technologies have redefined priorities across the Medical Device sector, influencing how the Nephrostomy Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Technological Advancements in Nephrostomy Devices

The development of nephrostomy devices has moved them from simple drainage tools to sophisticated interventional tools which have a direct effect on market growth. Nephrostomy catheters produced with more robust materials, featuring improved ergonomics and infection prevention, such as the balloon dilatation catheter and the BioCath catheter with hydrogel coating, have proven to be successful in reducing the risks of perirenal haematoma and device related infections. The clinical advantages of these technologies are leading to a rise in the number of healthcare professionals adopting them for urological procedures. As a result, a significant value premium exists, and it is forecast that this trend will add approximately $196 million to the Nephrostomy Tubes market by the year 2030. In line with healthcare institutions focusing on minimally invasive surgical procedures that are safer and more efficient, manufacturers are able to differentiate their products and expand their market through the release of Nephrostomy devices of the latest technology.
02

Shift Toward Advanced Catheter Technologies

The nephrostomy devices industry is transitioning from basic drainage tubes to advanced catheter technologies that emphasize safety, durability, and patient comfort. Innovations such as hydrophilic coatings, kink-resistant materials, antimicrobial surfaces, and balloon-retained designs improve placement accuracy and reduce infection and dislodgement risks. This transition enhances outcomes in interventional radiology and urology, while also influencing medical materials and infection-control solution providers, which now collaborate closely with device manufacturers. Hospitals benefit from lower complication rates and shorter lengths of stay, improving cost efficiency. The shift supports wider adoption of nephrostomy procedures in both acute and long-term care settings.